[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Phramongkutklao College of Medicine and Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100621117","high-dose-vs-standard-ergocalciferol-for-vitamin-d-normalization-in-aggressive-non-hodgkin-lymphoma-100621117",false,"NCT07366450","High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma","Safety and Efficacy of High-Intensity Loading Dose Versus Standard Weekly Dosing of Ergocalciferol (Vitamin D2) for Vitamin D Normalization in Patients With Newly Diagnosed Aggressive Non-Hodgkin Lymphoma: A Randomized, Open-Label, Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 20 years.\n* Newly diagnosed aggressive non-Hodgkin lymphoma, confirmed by histopathological examination according to the WHO Classification of Haematolymphoid Tumours, 5th edition, with an indication for standard first-line chemoimmunotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n* Serum 25-hydroxyvitamin D level \\\u003C 30 ng\u002FmL within 14 days prior to randomization.\n* Adequate organ function to receive full-dose standard chemotherapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Mild hypercalcemia (corrected Ca \\> 10.4 mg\u002FdL)\n* Hyperphosphatemia (PO4 \\> 4.5 mg\u002FdL)\n* History of urolithiasis associated with hypercalciuria or a diagnosis of primary hyperparathyroidism.\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Inability to take oral medication, active gastrointestinal bleeding, or malabsorption syndrome.\n* Pregnancy or breastfeeding.\n* Prior systemic therapy for lymphoma.\n* Ongoing tumor lysis syndrome requiring urgent treatment.\n* Prior use of vitamin D supplements (ergocalciferol or cholecalciferol).\n\nWithdrawal Criteria:\n\n* Development of mild hypercalcemia.\n* Development of mild hypophosphatemia.\n* Development of hypervitaminosis D.\n* Occurrence of severe adverse events (AEs) or side effects for which the investigator considers discontinuation of the study drug necessary for patient safety.\n* Investigator's judgment that continued participation may pose a safety risk, such as the occurrence of serious infection, febrile neutropenia, or organ failure.\n* Non-adherence to study medication, defined as cumulative vitamin D₂ intake of less than 80% of the expected cumulative dose at the time of serum vitamin D assessment.\n* Participant withdrawal of consent to continue participation in the study.","ALL","20 Years",{"count":19,"type":20},52,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.\n\nThe main questions it aims to answer are:\n\n* Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?\n* Are there differences in safety and adverse events between the two dosing strategies?\n\nResearchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)\n* Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma\n* Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits\n* Be followed for treatment response, survival outcomes, and adverse events during and after therapy",[26,27],"Vitamin D 25-Hydroxylase Deficiency","Lymphoma Non-Hodgkin",[29,30,31,32],"Non-Hodgkin lymphoma","Vitamin D deficiency","Overall survival","Efficacy","NOT_YET_RECRUITING","2026-01-16",{"date":36,"type":37},"2026-01-26","ACTUAL",{"date":39,"type":20},"2026-02-01",{"date":41,"type":20},"2029-07-31",{"name":43,"class":44},"Phramongkutklao College of Medicine and Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100594048","alternative-vs-once-daily-oral-iron-supplementation-in-iron-deficiency-anemia-ida-100594048","NCT07014371","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)","Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA): A Multicenter, Randomized, Open-Label, Non-Inferiority Trial","Inclusion Criteria:\n\n* Male or female patients aged ≥20 years diagnosed with iron deficiency anemia, defined as: hemoglobin (Hb) \\\u003C13 g\u002FdL in males or \\\u003C12 g\u002FdL in females, and ferritin \\\u003C50 ng\u002FmL or transferrin saturation (TSAT) \\\u003C20%.\n* No iron supplementation within the past 3 months.\n\nExclusion Criteria:\n\n* Hemodynamic instability (e.g., acute bleeding or hypotension).\n* Severe heart failure (New York Heart Association \\[NYHA\\] Class III-IV) or other active cardiac diseases.\n* Active malignancy or history of cancer within the past 3 years (except non-melanoma skin cancer).\n* Pregnancy or breastfeeding.\n* Chronic liver disease including cirrhosis (Child-Pugh class B or C).\n* Chronic kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n* Clinically significant thalassemia or hemoglobinopathies.\n* Ongoing infection or chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Malabsorption disorders (e.g., history of bariatric surgery).\n* Red blood cell transfusion within the past 3 months.\n\nWithdrawal Criteria\n\n* Withdrawal of informed consent.\n* Severe adverse events requiring permanent discontinuation of study medication.\n* Investigator's judgment that continued participation poses a safety risk.\n* Non-adherence to study medication (compliance \\\u003C 75%).\n\nTreatment Failure\n\n\\- Increase in hemoglobin level of \\\u003C 1 g\u002FdL at Week 4 or Week 8 compared with baseline.",{"count":54,"type":20},114,[23],"The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are:\n\nIs alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels?\n\nWhat are the side effects associated with each dosing regimen?\n\nResearchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects.\n\nParticipants will:\n\nBe randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks\n\nUndergo blood tests and clinical assessments at baseline, Week 4, and Week 8\n\nReport any side effects and bring remaining pills to evaluate medication adherence\n\nThis is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.",[58],"Iron Deficiency Anemia Treatment",[60,61,62,63],"Iron deficiency anemia","Ferrous fumarate","Alternate day dosing","Hemoglobin","RECRUITING","2026-01-05",{"date":67,"type":37},"2026-01-07",{"date":69,"type":37},"2025-06-09",{"date":71,"type":20},"2027-12-31",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100573503","phase-2-efficacy-of-montelukast-in-preventing-transaminase-elevation-in-adult-dengue-patients-100573503","NCT06747130","Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients","Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients: a Randomized, Double-blind, Placebo Controlled, Superiority Trial","Inclusion Criteria:\n\n* Patient age \\>18 years\n* Dengue infection diagnosed by NS1 antigen, or polymerase chain reaction\n* Admitted to the hospital\n* Written informed consent from patient or attending relative able to and willing to give informed consent\n\nExclusion Criteria:\n\n* Other possible cause of fever other than dengue infection\n* Pregnancy\n* Unable to take medication\n* Aminotransferase level above 150 U\u002Fl\n* Allergy to paracetamol or tramadol\n* Paracetamol indicated for condition other than dengue infection\n* Critically ill patient who need ICU or invasive ventilation support\n* History of cirrhosis\n* Unable to communicate\n* Other indication of montelukast\n* History of psychiatric illness",{"count":81,"type":20},82,[83,84],"PHASE2","PHASE3","The goal of this clinical trial is to learn if drug montelukast works to treat dengue in adults. It will also learn about the safety of drug montelukast . The main questions it aims to answer are:\n\nDoes drug montelukast lower the incidence of liver enzyme elevations in participants ? What medical problems do participants have when taking drug montelukast ?",[87,88,89],"Dengue","Montelukast","Transaminases","2025-05-27",{"date":92,"type":37},"2025-05-29",{"date":94,"type":37},"2025-01-31",{"date":96,"type":20},"2027-01",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100554222","phase-3-lemborexant-on-improving-sleep-quality-among-hospital-rotating-shift-workers-100554222","NCT06496282","Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers","The Efficacy of Lemborexant Versus Placebo on Improving Sleep Quality Among Hospital Rotating Shift Workers: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Age 20-60 years\n* Rotating shift workers at least 3 months and continue rotating shift until end of study\n* Participants who have sleep problem especially total sleep time lower than 6 hours and\u002For unable to sleep effectively according to the ICSD-3 at least 1 criteria\n* Participants who have sleepy while working and have Epworth sleepiness scale in shift grater than or equal to 10 points\n\nExclusion Criteria:\n\n* Receiving drug interaction esp. drugs induced CYP3A4 (moderate to severe) or drugs inhibited CYP3A4 (moderate to severe)\n* Untreatment mental health disease or in process medication adjustment\n* Hepatic function in Chid-Pugh C\n* Pregnancy\n* Breastfeeding\n* Participants who in process medication adjustment such as mental heat, neurology, insomnia, contraceptive drugs.\n* Diagnosis obstructive sleep apnea (OSA) with or without CPAP using or diagnosis restless leg syndrome or circadian rhythm disorders or narcolepsy\n* Complex sleep behaviors such as sleep driving, sleep phone, sleep cooking\n* HAM-D grater than or equal to 24 points\n* HAM-A grater than or equal to 24 points\n* Caffeine taking grater than 400 mg\u002Fday or can't not hold caffeine 4 hours before bedtime\n* Substance abuse or alcoholism within 2 years ago\n* Alcohol intake grater than 140 g of alcohol per week in female or intake grater than 210 g of alcohol per week in male or can't control alcohol drinking greater than 20 g of alcohol per day or can't hold alcohol within 3 hours before bedtime\n* Cannabinoid using within 1 week ago\n* Participants who have underlying disease such as stroke, atrial fibrillation, chronic obstructive pulmonary disease, hepatic impairment, severe renal impairment, cognitive impairment, cancer, chronic pain\n* Participant who use of benzodiazepine or non-benzodiazepine in treatment of insomnia\n* Participant who have nocturia problem\n* Participant who have mental health problem which the physician conclude it affect the safety of participant\n* Participant who have suicidal thinking with or without plan or have suicidal behaviors within 10 years ago\n* Participant who have major surgery schedule during the study\n* Travel across greater than 3 time zone within 2 weeks before include participant\n* Allergy of lemborexant or component of lemborexant\n* Have previously participated in study that used lemborexant\n* Participant who",true,"60 Years",{"count":108,"type":20},50,[84],"Shift Work Sleep Disorder (SWSD) are caused by working shifts with a wake-up schedule and sleeping in a way that is different from the natural way of sleeping and avoiding sleep usually results in deviations. of the biological clock (Biological clock), which is an important cause of sleep problems including insomnia, excessive sleepiness or daytime sleepiness these problems was associated cadiovascular events, decrease quality of life and long term working. At the present there are limited information regarding the effectiveness of medications used to promote sleep in shift workers. Lemborexant is specific in binding to orexin type 2, which has a direct effect on sleep. and there are limited biomarkers monitoring from the use of lemborexant including still not found. Which studies have followed depressive symptoms, anxiety symptoms and cognition from a group of people with insomnia, the aim of study to assessment effectiveness of lemborexant on sleep efficiency, quality of life, symptoms of depression, cognition, BDNF, CRP, IL-6 and TNF-alpha levels. of volunteers working on rotating shifts.",[112],"Sleep",[114,115,116,117,118,119],"Shift workers","Improving sleep","Lemborexant","Orexin receptor antagonists","Hospital rotating shift workers","Rotating shift workers","2024-07-03",{"date":122,"type":37},"2024-07-11",{"date":124,"type":20},"2024-08",{"date":126,"type":20},"2026-07",{"name":43,"class":44},""]